Ron Elwell, CEO and Founder of IPM.ai Wins MM+M’s Pinnacle Award

By: Dan Fisher, Principal, IPM.ai

Ron Elwell, CEO and founder of IPM.ai is a proud recipient of MM+M’s Pinnacle Award. This is the second year of the program, which honors 25 of the medical marketing industry’s most venerable marketers, strategists and creators. Although these industry leaders have reached peaks in their careers and shaped the industry, their work and commitment to innovation is ongoing. 

“Medical marketing is an ever-changing business, which makes staying ahead of trends and new technologies almost a full-time job in itself,” said MM+M editor-in-chief Larry Dobrow. “That makes the achievement of Pinnacle Award honorees even more impressive: Not only have they evolved with the times, but they’ve also continued to operate at a high level throughout.”

Ron has been a career-long disrupter, approaching business challenges with an outsider’s perspective. After observing that gene sequencing was enabling development of specialty/rare disease therapies while blockbuster drugs were losing patent rights, Ron created IPM.ai. IPM.ai utilizes ML/AI technologies and an extensive Real World Data universe to discover undiagnosed and misdiagnosed specialty and rare disease patients. 

By upending traditional – and ineffective – approaches to patient-finding, Ron is providing increased incentive for companies to more effectively research, develop, study and commercialize life-saving therapies quicker and with less risk. To date, IPM.ai has helped over 70 companies more effectively develop new molecules, conduct clinical studies and launch new drugs that have markedly improved quality of life. 

Ron hopes this award will encourage others to solve intractable problems in healthcare with fresh approaches.

About the Author

Dan Fisher

Principal, IPM.ai 

As Principal for IPM.ai, Dan leads a team that utilizes machine learning, artificial intelligence and advanced analytics to deliver valuable insights that guide and accelerate the clinical and commercial decisions of life sciences companies. With a focus on specialty markets, Dan’s deep expertise in rare disease and oncology disease states helps biopharma clients better understand and more effectively uncover ideal patients and their health care providers. Prior to joining IPM.ai, Dan led commercial operations and clinical analytics projects for ZS Associates. He holds a Master of Business Administration (MBA) from Vanderbilt University.